What Is a Depression Screening? What to Expect

A depression screening is a short set of standardized questions designed to flag whether you might be experiencing depression, so a provider can decide whether a more thorough evaluation is needed. The most widely used version, the PHQ-9, takes about two to three minutes and asks how often you have felt certain symptoms over the past two weeks. The U.S. Preventive Services Task Force recommends screening for depression in all adults, including pregnant and postpartum individuals and older adults.¹ If you have one coming up and are wondering what it involves, the process is far simpler than most people expect.

How the Questionnaire Works

The screening you are most likely to encounter is the Patient Health Questionnaire-9, or PHQ-9. It has nine items, each tied to one of the core symptoms of depression: low mood, loss of interest, sleep changes, fatigue, appetite changes, feelings of worthlessness, trouble concentrating, noticeable slowing down or restlessness, and thoughts of self-harm. For each item, you pick how often you have been bothered by that symptom over the last two weeks, on a scale from “not at all” (0 points) to “nearly every day” (3 points). Your total score falls somewhere between 0 and 27.²

Scores of 5, 10, 15, and 20 roughly correspond to mild, moderate, moderately severe, and severe depression.² In most primary care settings, a score of 10 or above triggers a closer look. In a diagnostic accuracy study, the PHQ-9 showed a sensitivity near 90% and a specificity around 78%, meaning it catches most true cases while still letting some non-depressed people through as false positives.³ That trade-off is intentional. Screenings are designed to err on the side of catching people who need help rather than missing them.

Sometimes your provider will start with an even shorter version. The PHQ-2 asks just two questions: whether you have had little interest or pleasure in doing things, and whether you have been feeling down, depressed, or hopeless. A score of 3 or higher on the PHQ-2 has been shown to have a sensitivity of 83% and a specificity of 92% for detecting major depression, and if you score above that threshold your provider will typically follow up with the full PHQ-9.⁴ A pooled analysis of ultra-short screening tests found that two- and three-item tools catch roughly three-quarters of true depression cases and miss relatively few, with a negative predictive value above 93%, meaning that if you screen negative, you almost certainly do not have depression.⁵

A Screening Is Not a Diagnosis

This is one of the most important things to understand. Scoring above the cutoff does not mean you have depression. It means you need a follow-up conversation or a more structured clinical interview to find out. Depression prevalence estimated through screening questionnaires runs around 31%, but when researchers use formal diagnostic interviews, that number drops to roughly 17%.⁶ The gap reflects the fact that screening tools are meant to cast a wide net. Plenty of people who score positive on a questionnaire turn out, on closer examination, to be going through temporary stress, grief, physical illness, or other conditions that mimic depression symptoms without meeting the full clinical criteria.

One study of primary care patients found that about a quarter of people diagnosed with depression by their family doctor did not actually meet the criteria when evaluated more carefully.⁷ That does not mean screenings are useless. It means the screening is step one, not the final word. A good provider uses the questionnaire result as a starting point for a conversation, not as a prescription pad trigger.

What Happens After You Score Positive

If your score suggests possible depression, the next step depends on your provider and the setting. In a large study of adults who screened positive, about 38% received an antidepressant prescription or a referral to mental health services right away, and by eight weeks that number climbed to 70% when follow-up contacts were included.⁸ In practice, the provider will usually ask you more detailed questions about what you have been experiencing, how long it has been going on, and whether there are stressors or life changes that might explain your symptoms. They may ask about sleep, appetite, energy levels, and suicidal thoughts in more depth than the written questionnaire covered.

A positive screen does not automatically mean medication. Depending on severity, the plan might be therapy alone, medication, a combination, a referral to a specialist, or simply a follow-up appointment in a few weeks. The research does highlight a gap between screening and follow-through, though. In one study of pregnant women who screened positive, most were recommended for therapy, but most did not actually receive it.⁹ Adolescents who were screened had better odds of getting follow-up care compared with those who were not screened at all.¹⁰ The screening itself makes follow-up more likely, even if the system is not perfect at delivering it.

The Question About Suicidal Thoughts

The ninth item on the PHQ-9 asks whether you have had “thoughts that you would be better off dead or of hurting yourself in some way.” This catches many people off guard, and understandably so. But research into how patients experience this question is reassuring. In a study of primary care patients asked about suicidal thoughts during routine visits, everyone who participated felt the question was appropriate to ask. People who had experienced suicidal thoughts said that direct communication with a provider they trusted, one who listened and showed empathy, made them more comfortable disclosing.¹¹

That said, some patients who disclosed suicidal thoughts reported experiencing stigma afterward. The quality of the conversation matters. A provider who asks the question on a form and then barely acknowledges the answer is not doing the same thing as a provider who uses it as a doorway into a real discussion. If you answer “yes” to this item, your provider should ask follow-up questions about the nature of those thoughts, whether you have a plan, and whether you feel safe. If they score above a certain threshold, in some clinics this triggers a same-day safety assessment.

Honesty and Comfort During Screening

Screening only works if people answer truthfully, and a significant number of people do not. In a study of mothers screened during pregnancy and the postpartum period, about one in five admitted they had not always answered honestly when asked about their emotional well-being. The reasons fell into a few patterns: they normalized their symptoms and figured they were coping fine, they worried about being judged, they feared consequences like child protective services involvement, or they simply did not trust the confidentiality of the process.¹²

The same study found that women who felt uncomfortable during screening were four times more likely to have perinatal depression, which creates a painful catch-22: the people who most need to be identified are the ones least likely to disclose. If you find yourself tempted to minimize your answers, it is worth knowing that a positive screen does not go on a permanent record that follows you around, and providers are bound by the same confidentiality rules that apply to any other medical information. The screening is not a test you pass or fail. It is a tool to help you get support.

Screening for Teens

Adolescents are screened using a modified version of the PHQ-9 (called the PHQ-9-A or PHQ-9-M), adapted with language that fits how younger patients experience and describe their symptoms. The USPSTF recommends screening for depression starting at age 12. Implementation has been uneven, but practices that adopted universal screening saw dramatic improvements. One quality-improvement project at a community health center saw screening rates jump from near zero to 70% within six months, and overall referrals to mental health services increased as well.¹³ Another found that implementing universal screening raised documented depression diagnoses to about 12% and mental health referrals to 8%, numbers that were essentially zero before screening was routine.¹⁴

Large-scale data from almost 100,000 adolescent screenings found that about 6% scored in the threshold range for depression symptoms and roughly 7% endorsed some form of suicidality. Heightened risk was seen among older adolescents (15 to 17), female patients, Black and Hispanic/Latino youth, those attending urban practices, and those on Medicaid.¹⁵ For parents wondering whether their teen’s yearly physical will include this: it increasingly does. If you are a teen reading this, the form is not a trap. Your answers are confidential from your parents in most jurisdictions unless there is an immediate safety concern.

Screening During Pregnancy and After Giving Birth

Pregnant and postpartum individuals are typically screened with the Edinburgh Postnatal Depression Scale (EPDS), a 10-item questionnaire that avoids physical symptoms like fatigue and appetite changes that overlap heavily with normal pregnancy. The EPDS is usually given at least once during pregnancy and again after delivery. One study found that scores taken as early as day three postpartum predicted screening results a month later with reasonable accuracy: women who scored higher in those first few days were more likely to screen positive for depression at one month.¹⁶

The EPDS has been translated into dozens of languages, though a systematic review found that many local-language versions had lower accuracy for identifying true cases compared with the original English version.¹⁷ That matters because perinatal depression is a global issue, and relying on a screening tool that was validated in one cultural and linguistic context does not guarantee it works equally well everywhere.

Screening for Older Adults

Depression in older adults often looks different from depression in younger people. Sadness may be less prominent; instead, symptoms like withdrawal, vague physical complaints, cognitive slowing, and loss of motivation dominate. Standard screening tools sometimes miss these presentations, which is why the Geriatric Depression Scale (GDS) was developed. The five-item version of the GDS has strong accuracy, with a sensitivity of 94% and a specificity of 81%, and has been shown to perform as well as the longer 15-item version.¹⁸ It has also been validated across different cultural settings.¹⁹

Despite having validated tools, providers face real barriers to screening older adults. In one survey, 95% of primary care physicians cited short consultation time as a barrier, and 90% pointed to the challenge of managing multiple other health conditions that compete for attention during the visit.²⁰ Stigma plays a role too. Older patients may view depression as a personal weakness rather than a medical condition, and providers themselves sometimes lack training or resources to act on a positive result.²¹

Screening When You Have a Chronic Illness

Depression rates are higher among people living with heart disease, diabetes, chronic pain, and similar conditions. Some health systems have integrated depression screening into routine chronic disease management. A large cohort study of patients with coronary heart disease or diabetes found that screening significantly increased the rate of new depression diagnoses and antidepressant treatment, though the number needed to screen to produce one new diagnosis was high, around 976.²² The number needed to screen to trigger new antidepressant treatment was somewhat lower, around 687.

An important caveat: while treating depression improves quality of life, there is currently no strong evidence that treating depression in people with chronic disease improves the chronic disease itself. A technology assessment reviewing the available studies found no significant evidence that managing depression led to better outcomes for the underlying physical condition, even though some studies in heart disease patients were suggestive of benefit.²³ That does not diminish the value of treating depression on its own merits, but it is worth knowing that screening for depression in this context is about your mental health, not about magically improving your blood sugar or cardiac outcomes.

Digital and Online Screening

You might encounter a depression screening on a tablet in a waiting room, in a patient portal before a telehealth visit, or even through a standalone app. A systematic review found negligible differences in the measurement properties of online versus paper versions of validated screening tools.²⁴ In other words, filling out a PHQ-9 on a screen works just as well as filling it out on paper. Some people actually prefer the digital version because it feels less like a face-to-face interrogation, which can reduce the discomfort that leads to dishonest answers.

One thing to be careful about: free depression “quizzes” on random websites are not the same as validated clinical screening tools. If you take a self-assessment online, make sure it is based on a recognized instrument like the PHQ-9 or EPDS, and treat the result as information to bring to a provider, not as a diagnosis.

Why the Same Questionnaire Does Not Work Everywhere

Depression screening tools were largely developed in English-speaking, Western clinical settings. Translating them into another language is the easy part. The harder challenge is making sure the concepts behind the questions are relevant in a different cultural context. A scoping review of efforts to adapt depression scales for Indigenous populations found that cultural relevance, not just linguistic translation, was essential. Researchers used participatory methods and qualitative interviews to identify items that did not translate conceptually, and revised administration procedures to be culturally safe.²⁵

Similar challenges have emerged in adapting tools for adolescents in Nigeria, where certain items were considered unacceptable to discuss or carried strong stigma.²⁶ And in Samoa, researchers produced the first cross-culturally adapted mental health screening instruments for local adolescents, noting that further validation was still needed.²⁷ The broader point: if a screening tool was not validated with a population that looks like yours, the results carry more uncertainty. That does not mean you should refuse to take it, but it is context worth having.

When Substance Use Complicates the Picture

Depression and substance use overlap heavily, and standard depression screening does not always capture that. The PHQ-9 was found to be less strongly associated with various forms of substance use, meaning it may identify your depression symptoms without flagging the substance use that is driving or worsening them.²⁸ Researchers have recommended that clinics implement substance use screening alongside depression screening, particularly for patients with severe depression or those who do not respond to initial treatment.²⁹ If you are dealing with both, bringing up substance use during or after a depression screening can help your provider create a more accurate and effective plan.

Blood Tests and the Future of Screening

Today’s depression screening is entirely questionnaire-based. There is no blood draw, no brain scan, no biomarker test in routine clinical use. But research in this direction is active. A large population study found that results from routine blood laboratory tests had good predictive value for distinguishing people with depression from those without, both in the general population and in people with metabolism-related chronic diseases.³⁰ The findings are promising but not yet translated into a clinical tool you would encounter at your next doctor’s visit. For now, the pencil-and-paper (or tablet-and-stylus) questionnaire remains the standard, and it works well enough that major medical organizations recommend it for everyone.